Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage by Bien, Justyna et al.
Hindawi Publishing Corporation
International Journal of Nephrology
Volume 2012, Article ID 681473, 15 pages
doi:10.1155/2012/681473
Review Article
Role of Uropathogenic Escherichiacoli VirulenceFactors in
DevelopmentofUrinaryTractInfectionand KidneyDamage
Justyna Bien,1 OlgaSokolova,2 andPrzemyslaw Bozko3
1Witold Stefanski Institute of Parasitology of the Polish Academy of Sciences, 51/55 Twarda Street, 00818 Warsaw, Poland
2Institute of Experimental Internal Medicine, Otto von Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany
3DepartmentofInternalMedicineI,FacultyofMedicine,UniversityofT¨ ubingen,Otfried-M¨ uller-Straße10,72076T¨ ubingen,Germany
Correspondence should be addressed to Przemyslaw Bozko, przemyslaw.bozko@med.uni-tuebingen.de
Received 1 August 2011; Revised 2 November 2011; Accepted 1 December 2011
Academic Editor: Lucia Andrade
Copyright © 2012 Justyna Bien et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Uropathogenic Escherichiacoli(UPEC) is a causative agent in the vast majority of urinarytract infections (UTIs),including cystitis
and pyelonephritis, and infectious complications, which may result in acute renal failure in healthy individuals as well as in renal
transplant patients. UPEC expresses a multitude of virulence factors to break the inertia of the mucosal barrier. In response
to the breach by UPEC into the normally sterile urinary tract, host inﬂammatory responses are triggered leading to cytokine
production, neutrophil inﬂux, and the exfoliation of infected bladder epithelial cells. Several signaling pathways activated during
UPECinfection,includingthepathwaysknowntoactivatetheinnateimmuneresponse,interactwithcalcium-dependentsignaling
pathways. Some UPEC isolates, however, might possess strategies to delay or suppress the activation of components of the innate
host response in the urinary tract. Studies published in the recent past provide new information regarding how virulence factors
of uropathogenic E. coli are involved in activation of the innate host response. Despite numerous host defense mechanisms, UPEC
can persist within the urinary tract and may serve as a reservoir for recurrent infections and serious complications. Presentation
of the molecular details of these events is essential for development of successful strategies for prevention of human UTIs and
urological complications associated with UTIs.
1.Introduction
Escherichia coli is a common inhabitant of the gastroin-
testinal tract of humans and animals. Usually, E. coli
forms a beneﬁcial symbiotic relationship with its host and
plays important roles in promoting the stability of the
luminal microbial ﬂora and in maintaining normal intestinal
homeostasis [1]. As a commensal, E. coli rather remains
harmlessly conﬁned to the intestinal lumen and rarely causes
a disease. However, in the debilitated or immunosuppressed
host, or when the gastrointestinal barriers are violated,
even nonpathogenic-commensal strains of E. coli can cause
infection [2]. Some strains of E. coli can diverge from their
commensal cohorts, taking on a more pathogenic nature.
These strains acquire speciﬁc virulence factors (via DNA
horizontaltransferoftransposons,plasmids,bacteriophages,
and pathogenicity islands), which confer an increased ability
to adapt to new niches and allow the bacteria to increase the
ability to cause a broad spectrum of diseases.
The pathogenic E. coli strains are broadly classiﬁed
as either enteric/diarrheagenic E. coli or extraintestinal E.
coli (ExPEC). Six diﬀerent E. coli “pathotypes,” including
enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli
(EHEC), enterotoxigenic E. coli (ETEC), enteroaggregative
E. coli (EAEC), enteroinvasive E. coli (EIEC), and diﬀusely
adherentE.coli(DAEC),aretheenteric/diarrheagenicE.coli,
and two pathotypes, neonatal meningitis E. coli (NMEC)
and uropathogenic E. coli (UPEC), are the most common
ExPEC [2, 3]. Several pathotypes of enteric/diarrheagenic E.
coligiverisetogastroenteritisbutrarelycausediseaseoutside
of the intestinal tract. On the other hand, the ExPEC strains
maintain the ability to exist in the gut without consequence
but have the capacity to disseminate and colonize other host
niches including the blood, the central nervous system, and
the urinary tract, resulting in disease [4].
Urinary tract infections (UTIs) are considered to be
the most common infections in humans. The development
of UTIs depends on anatomical factors, the integrity of2 International Journal of Nephrology
host defense mechanisms, and the virulence of the infecting
organisms [5]. UTIs are classiﬁed into disease categories
according to the site of infection: cystitis (the bladder),
pyelonephritis (the kidney) and bacteriuria (the urine) [6].
Successful establishment of infection by bacterial pathogens
requires adhesion to host cells, colonization of tissues, and,
in certain cases, cellular invasion, followed by intracellular
multiplication, dissemination to other tissues, or persistence.
Colonization of the urine in the absence of the clinical
symptoms is called asymptomatic bacteriuria (ABU). Most
patients with ABU do not need treatment, and in many
cases the colonizing by the ABU strains may help to prevent
infection by other more virulent bacteria [7–9]. The primary
causative agents responsible for more than 80% of all UTIs,
including both ABU and symptomatic UTIs, are strains of
uropathogenic E. coli [10–12].
UPEC is the cause of community-acquired UTIs and a
large portion of nosocomial UTIs, accounting for substantial
medicalcostsandmorbidityandmortalityworldwide[6,13–
15]. The ability of UPEC to cause symptomatic UTIs is
associated with expression of a broad spectrum of virulence
factors [16], with adhesive molecules being arguably the
most important determinants of pathogenicity [17].
In contrast to symptomatic UPEC, the reason why
A B Up a t i e n t sd on o td e v e l o ps y m p t o m si sn o tp r o p e r l y
understood. However, it has been explained by a number
of observations that many ABU strains are nonadherent and
nonhaemolytic [18–20]. The strain E. coli 83972, which was
isolated from a patient with ABU who had carried it for 3
years, has lost the ability to express functional P and type
1 ﬁmbriae and has, therefore, been able to persist without
triggering the host immune response. In contrast to the
microorganisms that have acquired genes encoding adhesins
for pathogenesis, E. coli 83972 is adapted to commensalism
through gene loss and mutation [21, 22].
The symptomatic strains of UPEC, which colonize the
urinary tract, may ascend towards bladder to cause cystitis,
which is usually associated with the classic symptoms of
UTIs, that is, pain (painful urination), frequency (frequent
urination), and urgency (sudden compelling desire to uri-
nate). However, UTIs can proceed from the bladder, via the
ureters to the kidney, to cause pyelonephritis with the possi-
bility of causing irreversible kidney damage and death [23].
Among Gram-negative bacteria, E. coli is the most frequent
pathogen inducing acute renal failure. Moreover, urological
complications, for example after renal transplantation, are
associated with UTIs and E. coli is the most common clinical
isolate [24–26]. Acute allograft injury in the renal transplant
population is also associated with both UPEC and clinical
diagnosis of upper UTIs [27].
In response to the breach by UPEC into normally sterile
urinary tract, the robust host innate response is triggered,
including the production of inﬂammatory cytokines and
chemokines. The production of inﬂammatory mediators
results in the rapid recruitment of neutrophils into the
bladder lumen and in bacterial clearance [28, 29]. Moreover,
the host inﬂammatory response leads to the exfoliation of
infected bladder epithelial cells and generation of reactive
nitrogen and oxygen species along with other antimicrobial
compounds [30, 31]. These bacteria might also possess
multitude of strategies to delay or suppress innate immune
response, which facilitate bacterial growth and persistence
within the adverse settings of the urinary tract.
This paper summarizes our knowledge about virulence
factors of UPEC, the inﬂammatory responses, and develop-
ment of tissue damage caused by UTIs.
The mechanisms by which EPEC stimulates proinﬂam-
matory response, including the role of Ca2+, and inﬂuence of
this response to development of cystitis and pyelonephritis
will also be discussed.
2. Virulence Factorsof Uropathogenic E. coli
UPEC strains encode a number of virulence factors, which
enable the bacteria to colonize the urinary tract and persist
in face of highly eﬀective host defense. UPEC isolates exhibit
a high degree of genetic diversity due to the possession
of specialized virulence genes located on mobile genetic
elements called pathogenicity islands [4, 32]. Virulence
factors of E. coli that have been potentially implicated
as important to establish UTIs can be divided into two
groups: (i) virulence factors associated with the surface of
bacterialcelland(ii)virulencefactors,whicharesecretedand
exported to the site of action [33].
2.1. Surface Virulence Factors. S u r f a c ev i r u l e n c ef a c t o r so f
UPEC include a number of diﬀerent types of adhesive
organelles(ﬁmbriae),whichpromotebacterialattachmentto
host tissues within the urinary tract.
The presentation of adhesive molecules (adhesins) by
UPEC is the most important determinant of pathogenicity.
UPEC adhesins can contribute to virulence in diﬀerent
ways: (i) directly triggering host and bacterial cell signaling
pathways,(ii)facilitatingthedeliveryofotherbacterialprod-
ucts to host tissues, and (iii) promoting bacterial invasion
[34].
Type1ﬁmbriaeareimplicatedasvirulencefactorsinani-
mal models of urinary tract infection, but their function in
human pathology remains unclear [35–39]. Role of the type
1 ﬁmbriae in human disease is diﬃcult to reconcile because
theyareexpressedinbothpathogenicandcommensalstrains
[40, 41]. Speciﬁcally, there is no signiﬁcant diﬀerence in the
ﬁm gene frequency between more or less virulent strains in
the urinary tract [42]. In the murine UTIs model, the type
1 ﬁmbriae have been shown to enhance bacterial survival, to
stimulate mucosal inﬂammation, and to promote invasion
a n dg r o w t ha sab i o ﬁ l m[ 17, 37, 43–46]. The type 1 ﬁmbriae
bind to the urothelial mannosylated glycoproteins uroplakin
Ia and IIIa (UPIIIa) via the adhesin subunit FimH, located
at the ﬁmbrial tip. This interaction leads to molecular
phosphorylation events, which are required for stimulation
of signaling pathways involved in invasion and apoptosis and
mayalsocontributetoelevationoftheintracellularCa2+ level
in urothelial cells [4, 17, 47]. Furthermore, Tamm-Horsfall
protein (THP) is produced by kidney cells into human urine
andcanactasasolubleFimHreceptor,obstructingbacterial-
host cell interaction and limiting the ability of UPEC to
colonize the urinary tract [48, 49].International Journal of Nephrology 3
P ﬁmbriae are the second common virulence factor of
UPEC, which plays an important role in the pathogenesis of
ascending UTIs and pyelonephritis in humans [50–52]. They
are responsible for adhesion to mucosal and tissue matrix
and for the production of cytokines [53–55]. P ﬁmbriae
consist of heteropolymeric ﬁbres composed of diﬀerent
protein subunits, encoded by the papA-K gene operon [56].
These ﬁmbriae recognize kidney glycosphingolipids carrying
the Gal α (1–4) Gal determinant on renal epithelia via its
papG adhesion [2, 57]. Attachment of P ﬁmbriae to this
receptor leads to the release of ceramide, which acts as an
agonist of Toll-like receptor 4 (TLR4), a receptor involved in
activation of the immune cell response [58]. This, in turn,
leads to the development of the local inﬂammation and pain
associated with UTIs [59]. Recently, Melican and coworkers
[60] have deﬁned previously unknown synergistic functions
of the both types of ﬁmbriae, which facilitate bacterial
colonization under dynamic in vivo conditions. P ﬁmbriae
havebeenshowntoenhanceearlycolonizationofthetubular
epithelium,whilethetype1ﬁmbriaemediatecolonizationof
the center of the tubule via a mechanism that involves inter-
bacterial binding and bioﬁlm formation. The heterogeneous
bacterial community within the tubule subsequently aﬀects
renal ﬁltration leading to total obstruction of the nephron.
The obstruction contributes to the full pathophysiology
of pyelonephritis [60]. In renal transplant patients, the P
ﬁmbriae are also the most common virulence factor and
papG class II allele is predominant class of the P ﬁmbriae
isolated from the patients with acute renal dysfunction.
Additionally, in the renal transplant patients with upper
UTIs, a majority have an acute allograft injury due to UPEC,
which express the P ﬁmbriae [27].
S ﬁmbriae and F1C ﬁmbriae are also implicated in the
process of UTIs. Both these types of ﬁmbriae show binding
to epithelial and endothelial cell lines derived from the lower
human urinary tract and kidney [34, 61, 62]. The S ﬁmbriae
may facilitate bacterial dissemination within host tissues and
are often associated with E. coli strains that cause sepsis,
meningitis, and ascending UTIs.
Both the ﬁmbrial Dr and aﬁmbrial Afa adhesins of E.
coli are associated with UTIs, in particular, with gestational
pyelonephritis and recurring cystitis [63–66]. Dr adhesins
bind to type IV collagen and decay-accelerating factor (DAF)
in the kidney [67]. Dr adhesins have been demonstrated to
display a tropism to the basement membrane of the renal
interstitium in a mouse model and, therefore, are critical for
development of the chronic pyelonephritis [68]. Mutation
within the dra region encoding for Dr ﬁmbriae prevents
development of the tubulointerstitial nephritis.
Adhesins of the Afa family are involved in UTIs [69], and
UPEC strains expressing these adhesins have a unique renal
tissue tropism [70, 71]. Clinical and experimental ﬁndings
suggest that E. coli strains with Afa adhesins have properties
potentially favoring the establishment of chronic and/or
recurrent infection [65, 69].
Virulence factors located on the bacterial surface include
also the capsule and the lipopolysaccharide (LPS). The
capsule is mainly a polysaccharide structure covering and
protecting the bacterium from the host immune system
[72]. The capsule provides protection against phagocytic
engulfment and complement-mediated bactericidal eﬀect in
the host. Certain capsular types, for example, K1 and K5,
show a molecular mimicry to tissue components, preventing
a proper humoral immune response of the infected host
[73]. The LPS is an integral component of the cell wall
of Gram-negative bacteria. LPS is known to activate host
response and to induce nitric oxide and cytokine production
[74]. Although LPS of UPEC is important in activation of
proinﬂammatory response in uncomplicated UTIs, it is not
clear whether LPS plays a role in mediating a renal failure
and acute allograft injury in patients with ascending UTIs.
It has been demonstrated in an animal model that the acute
renal failure due to LPS depends on the systemic response
to LPS and does not depend on expression of functional
LPS receptor, TLR4, in the kidney [75]. However, TLR4
is expressed in renal epithelia and in the renal pelvis, and
these ﬁndings suggest that the ascending infection due to
E. coli may stimulate the innate immune response associ-
ated with the acute allograft injury in patients with UTIs
[76, 77].
Flagella, an organelle responsible for bacterial motility,
is involved in the interaction of various pathogenic E. coli
strains with epithelial cells. Flagellated UPEC cause 70–90%
ofallurinarytractinfections,andtheirpathogenesisinvolves
contact between the bacteria and epithelial cell surface of
theurinarytract.Thepyelonephritis-associatedE.colistrains
may invade renal collecting duct (CD) cells through ﬂagellin,
and the ﬂagellin acts as an invasin in this process [78].
Other studies have suggested that E. coli ﬂagella may be
of importance in allowing the bacteria to ascend from the
bladder and to initiate kidney infection in humans. The use
of an antibody against the ﬂagella could prevent the spread
of UPEC into the kidneys [79].
2.2. Secreted Virulence Factors. Toxins are important viru-
lencefactorsinavarietyofE.coli-mediateddiseases.Produc-
tion of toxins by colonizing E. coli may cause an inﬂamma-
tory response, a possible pathway for UTIs symptoms. The
most important secreted virulence factor of uropathogenic
E. coli is a lipoprotein called α-haemolysin (HlyA), which
is associated with upper UTIs such as pyelonephritis [73].
The HlyA is a pore-forming toxin, which belongs to the
family of RTX (repeats in toxin) toxins that are widespread
among the Gram-negative pathogens [80, 81]. This toxin
has been shown to exert dual concentration-dependent
activities on primary epithelial cells originating from renal
proximal tubules [82]. At high concentrations, HlyA is able
to lyse erythrocytes and nucleated host cells, a process
that may enable extraintestinal pathogens like UPEC to
better cross mucosal barriers, damage eﬀector immune
cells, and gain enhanced access to host nutrients and iron
stores [73, 83, 84]. At low concentrations, HlyA can induce
the apoptosis of target host cells, including neutrophils, T
lymphocytes, and renal cells, and promote the exfoliation
of bladder epithelial cells [85–88]. HlyA has also been
shown to induce Ca2+ oscillations in renal epithelial cells,
resulting in increased production of IL-6 and IL-8 [89].
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to renal complications, are caused by HlyA. The E. coli-
expressed α-hemolysin may induce endothelial damage and
renal vasoconstriction, for example, by the intrarenal release
of endothelin [90]. Moreover, permanent renal scarring is
a common complication following HlyA E. coli infection
[91, 92] and may be independent of bacterial adherence
properties [93]. Moreover, it has been shown that HlyA and
other E. coli toxins cause inducible nitric-oxide-synthase-
(iNOS-) mediated cell membrane injury and apoptosis, a
process that is regulated by extracellular signal regulated
kinase (ERK) independently of the p53 pathway [94].
The cytotoxic necrotising factor 1 (CNF1) [95, 96]i s
produced by one-third of all pyelonephritis strains and may
also be involved in kidney invasion. In vitro, this protein is
secreted by E. coli and stimulates actin stress ﬁbers formation
and membrane ruﬄe formation in a Rho GTPase-dependent
manner, resulting in the entry of E. coli into the cells.
However, the detailed role of CNF1 in invasion processes
during pyelonephritis remains unclear and is a matter of
debate [30]. In vitro studies have also showed that CNF1
interferes with polymorphonuclear phagocytosis and evokes
apoptotic death of bladder epithelial cells [97, 98]. In vivo,
CNF1 may lead to bladder cell exfoliation and to enhanced
bacterial access to underlying tissue [97].
Secretedautotransportertoxin (SAT)is avirulencefactor
of pyelonephritis E. coli strains. SAT has a toxic activity
against cell lines of bladder or kidney origin and, thus, may
be important for pathogenesis of UTIs [99, 100]. Moreover,
the cytolethal distending toxin (CDT) could be also consid-
ered as a virulence factor in UTIs caused by E. coli [101, 102].
Toll/interleukin (IL-1) receptor (TIR) domain-containing
protein (Tcp) represents a novel class of virulence factors,
which are able to subvert TLR signaling to gain a survival
advantage during UTIs. Importantly, UPEC encoding Tcp
promotes bacterial survival and kidney pathology in vivo
[103].
3. Host Defenses againstUPEC Colonization of
the UrinaryTract
The urinary tract is a typically sterile environment, which
is maintained by a variety of host mechanisms to prevent
bacterial colonization and survival. Most of the pathogenic
bacteria, which cause UTIs, are from the host own bowel
ﬂora and enter the bladder via the urethra. Uroepithelial
adherence is critical for establishment of UTIs. UPEC strains
possess an impressive repertoire of adhesins that enable the
bacteria to aggregate and adhere to the cellular surfaces
[34, 57, 62, 69, 104]. Consequently, the ﬁrst line of host
defense against UTIs is concentrated on preventing UPEC
adherence to the bladder mucosa.
3.1. Primary Bladder Defenses. The urinary tract has a num-
ber of specialized defenses against bacterial colonization,
keeping the urine sterile. The bulk ﬂow of the urine through
the bladder and micturition can work to rinse away nonat-
tached or weakly adherent microbes from bladder surface
[105]. Secretion of glucosamines by bladder transitional cells
prevents bacterial adherence by forming a mucin layer. The
low pH and presence of salts, urea, and organic acids in
urine can reduce bacterial survival within the urinary tract.
The Tamm-Horsfall glycoprotein acts as an antiadhesive
urinaryfactorbybindingtoUPECexpressingtype1ﬁmbriae
and forming the complex, which is then cleared by voiding
[106–109]. Defensins (a group of small, highly cationic
antimicrobialpeptides)arealsoproducedintheurinarytract
after exposure to the pathogens. Defensins have the capacity
to kill bacteria, fungi, and some encapsulated viruses. These
peptides attach to the anionic phospholipids on the cell
wall of pathogens and disrupt their cell membrane function,
increasing cell permeability and causing cell death [110].
3.2. Host Response and Consequences of UPEC Adherence and
Invasion. If a microbe manages to sidestep these constitutive
host defenses and makes contact with the urothelium, its
continued presence can trigger the activation of additional
host defense mechanisms, leading to exfoliation of infected
bladder epithelial cells and inﬂammation.
3.2.1. Exfoliation of Infected Cells. A key feature of inﬂam-
mation during UTIs is a disruption of the urothelial integrity
due to the exfoliation and subsequent excretion of infected
eukaryoticcells[111,112].ThisFimH-dependentexfoliation
process occurs via an apoptosis-like pathway that involves
the activation of caspases, cysteine proteases implicated in
the execution of apoptosis, and DNA fragmentation [16,
113]. The importance of this response as a host defense
is illustrated by the fact that the inhibition of exfoliation
with a pan-caspase inhibitor dramatically reduces bacterial
secretion from the bladder early in the infection. The
bacteria, which manage to escape from dying superﬁcial
cells before the exfoliation process is completed, can go
on to infect surrounding and underlying tissue [114]. This
may not only promote bacterial dissemination within the
urinary tract but could also allow UPEC to enter a sheltered
environment within the bladder, where bacteria can persist
for long time. Thus, exfoliation is a powerful mechanism of
eradication of both attached and internalized bacteria from
the bladder epithelium.
3.2.2. Inﬂammation. Upon successful adherence to the
uroepithelium, the presence of bacteria and bacteria fac-
tors/products within the urinary tract can trigger rapid and
robust responses from the host.
Infection with UPEC elicits both innate and adaptive
immuneresponses,althoughaneﬃcienthostdefenseagainst
urinary tract infection is reliant upon an early activation
of the innate immune response [115, 116]. This response
is characterized by the production of a number of proin-
ﬂammatory mediators, including cytokines and chemokines
[117–119]. Bladder and kidney epithelial cells appear to
be a major source of interleukin-6 (IL-6) and interleukin-
8 (IL-8) after infection with UPEC, which are important
in the development of local tissue damage [119–123]. IL-6
possesses a variety of proinﬂammatory functions, including
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production of acute phase proteins [124]. A high urinary
concentration of IL-6 during acute phase of pyelonephritis
has been shown to correlate with an increased risk of
permanent renal scars [125]. IL-6 gene polymorphisms
have been connected to susceptibility to UTIs, but not scar
formation in children [126]. IL-8 is a potent neutrophil
chemotactic molecule. In humans, the induction of IL-8
after infection with UPEC correlates with appearance of
neutrophilsintheurine[119].Neutrophilrecruitmenttothe
site of infection has been shown to be critical for bacterial
clearancefromboththebladderandkidney,andthepresence
of neutrophils in the urine is a hallmark of UTIs. However,
their action may also lead to the local tissue damage [116].
Interactions between the neutrophil receptor CD11/CD18
and the adhesion molecule ICAM-1 on bladder epithelial
cells seem to be critical for neutrophil migration into the
urothelium [119].
Recently, it has been shown that IL-17A, an immun-
omodulatory cytokine, is involved in the innate immune
responsetoUTIs.AkeysourceofIL-17Aproductionappears
to be γδ-positive cells. IL-17A importance for the innate
immune response has been demonstrated by a defect in
acute clearance of UPEC in IL-17A−/− mice. This clearance
defect is likely a result of deﬁcient cytokine and chemokine
transcription and of impaired macrophage and neutrophil
inﬂux during infection [127].
In conclusion, explanation of the signaling pathways
involved in the neutrophil recruitment into the bladder and
kidneyshighlightstheimportanceofcytokinesandchemoki-
nes.
Importantly, activation of the innate immune response
has a dual eﬀect: it is necessary for eradication of pathogenic
bacteria but may also lead to tissue damage and permanent
scarring.
(1) Host Signaling in Response to UPEC Recognition. The
activation of the innate immune response in the urinary
tract is dependent on recognition of bacterial compo-
nents/products by TLRs [128–131]. In recent years, it has
become clear that the immune activation of bladder and kid-
ney epithelial cells depends on TLRs, including TLR4, TLR5,
and TLR11 [74, 77, 128, 129, 132]. Recognition of virulence
factors by TLRs stimulates signaling pathways resulting in
activationandtranslocationofNF-κB.Inthenucleus,NF-κB
activates the transcription of proinﬂammatory genes, such
as those encoding IL-6 and IL-8. NF-κB is one of the major
transcription factors required for induction of proinﬂamma-
tory response. However, in response to bacterial products,
the bladder epithelial cells can activate NF-κB-independent
signaling pathway (see below) [133]. More recently, the
involvement of interferon regulatory transcriptional factor
IRF3 in antibacterial defense and immunoregulation by
TLRs has received more attention [134–137]. Possession
of multiple signaling pathways for production of cytokines
is advantageous in case when bacteria have an ability to
suppress certain signaling events important for cytokine and
chemokine production (Figure 1).
TLR4 attracts most of the attention in context of the
mechanisms of immune defense in the urinary tract. TLR4
is responsive to LPS of Gram-negative bacteria. TLR4 is
expressed on the epithelial cells throughout the urinary
tract and is required to mount an eﬀective inﬂammatory
response after infection with UPEC [75]. However, both the
role of UPEC LPS and an existence of another bacterial
trigger of TLR4 signaling are an area of debate [54, 74,
117]. Several reports have claimed that uroepithelial cells
are refractory to LPS stimulation and have argued that,
instead, bacterial ﬁmbriae such as the type 1 ﬁmbriae, P
ﬁmbriae drive the induction of cytokines in these cells [130,
138]. Studies using the human kidney cell line indicate that
TLR4-mediated signaling pathway in response to UPEC is
dependent on P ﬁmbriae and can be initiated independently
of LPS/CD14 [54, 58, 130, 139]. Recently, the new IRF3-
dependent signaling pathway, which leads to induction of
the innate immune response in TLR4- and P-ﬁmbriae-
dependent manner, has been described. Mechanistic details
regarding this phenomenon include P ﬁmbriae binding to
surface glycosphingolipids (GSLs) and subsequent release
of the GSL membrane-anchoring domain, ceramide [58,
140]. This molecule appears to act as a TLR4 agonist and
the putative intermediate for TLR4 signaling initiated by
Pﬁ m b r i a e[ 58]. Ceramide-induced TLR4 signaling causes
rapid phosphorylation of proteins, including TRAM, PLC,
Fyn, PKA, p38 MAP kinase, ERK1/2, and CREB, which are
implicated in nuclear translocation of IFR3 and activation
of IRF3/IFNβ-dependent antibacterial eﬀector mechanisms
[141]. The IRF3-dependent signaling pathway is essential for
the host defense and is critical for distinguishing pathogens
from normal ﬂora at the mucosal barrier. In the absence
of IRF3 (in the Irf3-knockout mice) the acute mortality,
bacterial burden, abscess formation, and renal damage have
been observed, consistent with the need for this pathway
to maintain a functional antimicrobial defense. Relevance
of IRF3 pathway for human disease was supported by data
concerning polymorphic IRF3 promoter sequences, which
diﬀer between children with severe, symptomatic kidney
infection and children who were asymptomatic bacterial
carriers [141]. Recently, the FimH tip adhesin of type 1
ﬁmbriae has been shown to interact directly with TLR4—an
additional means for LPS-independent stimulation of TLR4
[142, 143].
However, other results underline the important role for
LPS and TLR4 in the stimulation of bladder epithelial cells
by type 1 ﬁmbriae E. coli [74, 118]. Stimulation of TLR4 by
LPS and type 1 ﬁmbriae correlates with the level of CD14
expression on bladder cells [117, 133, 144]. Interestingly,
CD14 expression is localized to the submucosa, and this may
suggest that uroepithelial cells exposed to the lumen have
little to no CD14 expression and, therefore, cannot respond
eﬃciently to LPS alone. These results support a role for both
LPS-dependent and cooperative TLR4 stimulation by UPEC
ﬁmbriae. The inﬂammatory response to LPS is mediated via
speciﬁc LPS-binding protein, accessory molecules CD14 and
MD2, and TIR domain. The TIR domain of TLR4 interacts
with the adaptors MyD88 and TIR domain containing
adaptor protein (TIRAP) [145]. Activation of TLR4 is
known to lead ﬁnally to p38 MAPK activation and nuclear6 International Journal of Nephrology
cAMP
CREB
PKA
PLC
Activation of 
dependent 
antibacterial 
mechanisms
Inﬂammatory response Cell death
Tissue damage
scarring    Neutrophils recruitment
Tissue damage/permanent
IL-6/IL-8
NF-kB
IFR3
p38 MAPK
-apoptosis, necrosis
CD14/MD2
MD88/TIRAP/TRAM
TLR4
Uropathogenic Escherichia coli
LPS/LBP/CD14
-Fimbriae -HlyA -LPS
GTP-ase RhoA
Ca2+
IFR3/IFNβ-
Adenyl cyclase3 (AC3)
Figure 1: Model of UPEC-induced signaling cascades in urothelial cells. Bacterial adherence to uroepithelium results in an epithelial
inﬂammatory response including local production of chemokines and cytokines or cell death via apoptosis. Activation of TLR4 through
virulence factors, including LPS and ﬁmbriae, triggers the response, which involves activation of kinases and subsequent translocation of
diﬀerent transcriptional factors such as NF-κB, CREB, and IFR3 into the nucleus. HlyA (through LPS-LBP-CD14 complex) is delivered to
the cell membrane and activates there GTPase RhoA, which is required for Ca2+ signaling. Speciﬁc HlyA-induced Ca2+ oscillations lead to
activation of NF-κB and synthesis of IL6/IL-8. Chemokine production leads to recruitment of neutrophils that kill the bacteria by producing
the cytotoxic substances. Tissue damage, cell death, and permanent scarring result in excessive inﬂammatory response.
translocation of NF-κB, and transcription of inﬂammatory
response genes (Figure 1).
TLR5 plays a crucial role in host defense to UPEC infec-
tion by mediating ﬂagellin-induced inﬂammatory responses
in the bladder [128, 146]. Hence, a study in TLR5−/− mice
challenged with UPEC demonstrated a decreased inﬂam-
matory response early after urethral bacterial infection and,
subsequently, a concomitantly increased bacterial burden in
both the bladder and kidney in these mice [128].
Recently, a new TLR11 expressed in the kidney, bladder,
and liver of mice was discovered [129]. Mice lacking
TLR11 are highly susceptible to infection of the kidneys by
UPEC indicating a potentially important role for TLR11
in preventing infection of internal organs of the urogenital
system [129]. In humans TLR11 might not play a signiﬁcant
role due to the abundance of stop codons occurring in the
human TLR11 gene.
(2) Genetic Polymorphism. Gene polymorphisms have been
shown to have an inﬂuence on the inﬂammatory response
of uroepithelium to bacteria as well as on susceptibility
to kidney damage. Polymorphism of the TLR4 gene is
associated with hyporesponsiveness to LPS, absence of
neutrophil recruitment, and delayed clearance of bacteria
from the urinary tract in mice [116]. Polymorphisms in
the TLR4 gene may also have a role in the inﬂammatory
response in humans. Lorenz et al. [147] have suggested that
the TLR4 Asp299Gly allele predisposes individuals to septicInternational Journal of Nephrology 7
shock and a higher prevalence of Gram-negative bacteremia.
Recently, Ragnarsd´ ottir et al. [148]h a v ed e s c r i b e dan e w
concept for human TLR variation, based on TLR4 promoter
polymorphisms that inﬂuence gene expression dynamics in
vitro and the innate immune response dynamics in patients
with asymptomatic bacteriuria. They suggest that reduced
TLR4 expression attenuates the innate mucosal response,
thus promoting an asymptomatic carrier state rather than
severedisease[148].Hawnetal.[149]haveshownthatTRL5
stop codon polymorphism abolishes ﬂagellin signaling and
is associated with increased susceptibility to Legionnaire’s
disease. These murine studies support a hypothesis that
individuals, who possess this TLR5 variant, will also be more
susceptible to UTI. Polymorphisms in cytokine genes have
also been connected to frequency and severity of urinary
tract infections, probably as a result of variability in immune
responses in such patients [150, 151]. For example, the gene
polymorphism associated with TNFα has been observed in
patients with reﬂux nephropathy [150]. Similarly, Cotton
et al. [151] have shown that variability in the transforming
growth factor-β1( T G F - β1) gene predisposes individuals
to postinfectious renal scarring. As previously described,
TGF-β1, the production of which is activated by other
cytokines (IL-6, IL-8, IL-1, and TNF-α), leads to the extra-
cellular matrix deposition through an increased synthesis
of matrix proteins, and at the same time by decreasing
matrix protein degradation following a suppression of
protease expression and an increased production of tissue
inhibitor of matrix metalloproteinases (TIMPs). All of these
facts support the hypothesis that TGF-β1i sa ni m p o r t a n t
factor in the pathogenesis of renal parenchymal scarring
followingUTI.Variableconstitutiveorinducedexpressionof
TGF-β1 protein could occur as a consequence of variability
in the TGF-β1 gene, which in turn could be associated
with diﬀerential eﬀects on cellular growth or extracellular
matrix deposition leading to renal parenchymal scarring
[152].
3.2.3. Ca2+Signaling during UPEC Infection is Important
for Innate Immune Response and Pathogenesis of Infection.
Several lines of evidence indicate that Ca2+-dependent sig-
naling pathway interacts with signal transduction pathways
implicated to the innate immune response. It supposes that
any eﬀect on Ca2+ regulation is likely to have some inﬂu-
ence on the innate immune response [153]. Interestingly,
expression of IL-8 has been shown to be under control
of artiﬁcially induced Ca2+ oscillations due to frequency-
modulated expression of the transcription factor NF-κ B.
Moreover, IL-6 is responsible for activation of response that
involves not only NF-κ B pathway, but also other signaling,
whichimplicatestwosecondarymessengers,Ca2+ andcAMP,
and mobilizes a transcriptional element known as cAMP
response element-binding protein (CREB) [133]. Diﬀerent
bacterial virulence factors can induce an increase of Ca2+
concentrations in the host cells [154–156]. α-Haemolysin
of UPEC elicits oscillatory ﬂuctuations of intracellular Ca2+
when present in the sublytic concentrations [89, 157]. It
has been shown that Ca2+ oscillations, corresponding to a
periodicityof12min,speciﬁcallystimulateproductionofIL-
6 and IL-8 in human renal epithelial cell [89].
Experiments designed to identify components of the
intracellular signaling pathway leading to Ca2+ oscillations
revealed that speciﬁc activity of HlyA is required together
with an activation of L-type Ca2+ channels to obtain Ca2+
oscillations. IP3-receptor-gated Ca2+ stores of the endoplas-
mic reticulum are involved [157, 158].
HlyA has long been known to physically interact with
LPS, which plays an indirect role in the cytolytic activity
of HlyA in erythrocytes and in epithelial cells [159–161].
Moreover, the ability of Hly to induce Ca2+ oscillations has
been suggested to require LPS as a cofactor. M˚ ansson et al.
[161] have shown that the LPS and HlyA complex exploits
the CD14/LPS-binding protein (LBP) recognition system
to bring HlyA to the cell membrane, where intracellular
Ca2+ signaling is initiated via speciﬁc activation of the small
GTPase RhoA. Additionally, HlyA-induced Ca2+ signaling
has been found to occur independently of the LPS receptor
TLR4. Also, the cytolytic eﬀect triggered by exposure of cell
to high HlyA concentrations occurs independently of the
CD14/LPS-LBP complex, suggesting that cytolysis is induced
through mechanism diﬀerent from that used for induction
of Ca2+ oscillations [161].
(1) TLR4-Mediated NF-B-Independent Signaling. Studies on
TLR4 signaling have revealed the existence of a distinct
TLR4-mediated signaling pathway leading to IL-6 secretion.
This pathway is present in the bladder epithelial cells and
is activated upon exposure to LPS [133]. Interestingly, this
signaling is independent of the pathway involving the NF-κB
and contains two well-known secondary messengers, Ca2+
and cAMP, which mobilize transcription factor CREB. The
CREB binds to cAMP-response element (CRE) promoter
sites to regulate the transcription of numerous genes in
response to a diverse stimuli [133, 162]. Intracellular cAMP
is an important second messenger in several signaling
pathways, including IL-6 response. The increase in cAMP
following bacterial exposure depends on both bacterial-
associated LPS and increase of intracellular Ca2+. This
E. coli-induced Ca2+-dependent cAMP production strictly
correlates with activation of adenyl cyclases (ACs). Because
there are currently ten known isoforms of mammalian ACs,
it is noteworthy that of the four ACs isoforms expressed in
bladder epithelial cells only adenyl cyclase 3 (AC3) is known
to be activated by increase in intracellular Ca2+ [163, 164].
E. coli-induced Ca2+ spike leads to AC3-mediated increase
in cAMP, protein kinase A (PKA) activation, and phospho-
rylation of the CREB [162]. Upon phosphorylation, CREB
promotes transcription of a number of genes, including IL-6
and IL-8 (Figure 1)[ 162, 165, 166]. Using selective blockade
of diﬀerent signaling pathways, it has been determined that
the activation of cytokine secretion by UPEC E. coli might
even be faster via the CREB than via the NF-κBp a t h w a y
[133]. The capacity of the bladder epithelial cells to mobilize
the secondary messengers and to evoke the rapid IL-6
response could be critical in their role as the ﬁrst responders
to microbial challenge in the urinary tract.8 International Journal of Nephrology
(2) UPEC FimH-Induced Elevation in Urothelial Ca. Acti-
vation of the host signal transduction cascades by bacterial
attachment is a well-recognized consequence of the host-
pathogen interactions [167], and urothelial signaling events
associate with UPEC invasion and urothelial cell apoptosis
[168]. FimH is involved in adhesion, invasion, and apoptosis
of urothelial cells and initiates bladder pathology by binding
to the uroplakin receptor complex. Recently, hitherto undis-
covered signaling role for the UPIIIa in bacterial invasion
and apoptosis has been presented. The UPIIIa is the only
major uroplakin with a potential cytoplasmic signaling
domain. In response to FimH adhesin binding, the UPIIIa
cytoplasmic tail undergoes phosphorylation on a speciﬁc
threonine residue by casein kinase II, followed by an increase
in intracellular Ca2+ concentration [47]. FimH-mediated
Ca2+ elevation occurs as a result of Ca2+ release from
intracellular stores and by inﬂux from extracellular sources.
Ca2+ elevation promotes global responses critical to UPEC
pathogenesis, including cytokine stimulation, membrane
traﬃcking, and apoptosis [133, 156].UPEC-induced UPIIIa
signaling is a critical mediator of the pathogenic cascade
induced in the host cell and is a novel therapeutic target.
3.2.4. UPEC Escapes from Host Innate Immune Response.
Several lines of evidence suggest that UPEC might possess
strategies to delay, attenuate, suppress, or subvert the activity
of components of the innate immune response in the
urinary tract, especially early in infection [16, 113, 169–
172]. Suppression of NF-κB activation by UPEC results in
enhanced type-1-ﬁmbriae-mediated apoptosis of urothelial
cells and in decreased levels of inﬂammatory cytokines
productionaswellasneutrophilrecruitment[113,170,172].
By hindering host cytokine expression and ensuing inﬂam-
matory responses, UPEC may be better able to establish
itself and multiply within the cells and tissues of the urinary
tract.
UPEC infection in the murine bladder upregulates ex-
pression of the suppressor of cytokine signaling 3 gene [112].
This phenomenon might represent a conserved strategy to
subvert host defenses, allowing UPEC to survive in the blad-
der. Additionally, several genes involved in LPS biosynthesis
(e.g., rfa and rfb)a n dsurA gene implicated in biogenesis of
outer membrane proteins are important for the phenotype,
suggesting that alternation in LPS structure may underline
the notstimulatory properties of UPEC [169, 172]. Hilbert et
al. [173] have shown that the bladder epithelial cells secrete
IL-6 and IL-8 in response to nonpathogenic E. coli but are
unabletomountthesamecytokineresponsefollowingexpo-
sure to UPEC, revealing dominant suppression of the innate
immune response through a pathway partially independent
of LPS and TLR4.
Recently it has been shown that TIR homologous protein
TcpCinhibitsMyD88-dependentgeneexpressionininfected
CF073 human uroepithelial cells [103, 174]. The eﬀects of
TcpC on bacterial persistence were attenuated in Trif−/− or
IL-1−/− mice, and innate immune responses were increased,
conﬁrming that Trif and IL-1-dependent targets might be
involved in vivo, in addition to MyD88. Loss of TcpC led
to decreased bacterial burden in kidneys and to reduced
renal damage, showing the importance of these proteins in
pathogenesis of the urinary tract infection.
Additionally, it has been shown that UPEC downregu-
lates neutrophil activity, a phenotype, which is important
during initiation and progression of infection, or for subse-
quent establishment of UPEC reservoir in the bladder [175].
The ability of UPEC to suppress the innate immune
response plays a role in persistence of pathogens within uri-
nary tract. However, identifying the gene(s) and factors that
are involved in this process will contribute to understanding
ofUPECpathogenesisandprovidepotentialnoveldiagnostic
and therapeutic targets.
3.2.5. Complications Associated with UTI. Renal bacterial
infections are common infectious diseases that can impair
renal function and/or lead to the renal tubulointerstitial
nephritis. Bacteria can invade the kidneys via the systemic
circulation or by local retrograde infection. They can cause
severe renal dysfunction and are associated with various
kidney diseases, such as IgA nephropathy, renal vasculitis,
and lupus nephropathy in postinfectious glomerulonephritis
[176–178].
In the previous sections we have described mechanisms
involved in induction of proinﬂammatory response to
UPEC. The innate immune system recognizes the virulence
determinants of pathogens via receptors and activates the
line of defense against pathogens. However, if functionality
of the proinﬂammatory response is delayed or suppressed,
bacteria after colonization the bladder can ascend the ureters
and the kidneys. At this juncture, a risk of permanent
renal scarring exists, and bacteria can access the blood-
stream [179]. In response to UPEC, the renal cells activate
proinﬂammatory mediators, which play essential roles in
the ﬁrst line of defense against pathogens in the kidney.
However, when this response is excessive, acute, or chronic
pyelonephritis may occur, leading to severe damage and
renal failure [180–182]. The acute pyelonephritis is an acute
inﬂammation of the renal parenchyma and pelvis associated
with bacterial infection. Clinically, the acute pyelonephritis
is a severe form of urinary tract infection with symptoms
that range from mild discomfort to life-threatening illness
or death [183]. Complications may result in chronic renal
scarring (atrophic pyelonephritis or reﬂux nephropathy) and
impairment of renal function [184, 185].
Thechronicpyelonephritishasbeendeﬁnedasadestruc-
tive inﬂammatory process involving both the pyelocaliceal
system and renal parenchyma [186]. The renal parenchymal
lesions include tubular atrophy, interstitial inﬂammation,
and interstitial ﬁbrosis. Parenchymal lesions may be relent-
lessly progressive and may result in end-stage kidney. UTIs
caused by UPEC are also the most frequent infectious
complications in renal transplant patients and can impair
long-term renal graft function [187].
In conclusion, further studies are required to determine
the mechanisms by which virulence factors of UPEC interact
with the kidneys and lead to the renal failure as well as to
the deterioration of renal allograft function. Concurrently,International Journal of Nephrology 9
better understanding of functions of virulence factors impli-
cated in renal damage could open the way to control the
immune response in the kidney and may be helpful for the
development of eﬀective therapies for E. coli-caused kidney
diseases.
4. Conclusion
Among the Gram-negative bacteria, UPEC is the pathogen
most frequently associated with UTIs. UPEC, which col-
onizes the urinary tract, may ascend towards bladder to
cause cystitis. Left untreated, bacteria ascend the ureters
to the kidney and establish a secondary infection, acute
pyelonephritis with the possibility of causing irreversible
kidney damage leading to kidney failure and death.
The speciﬁc host-pathogen interactions are required to
activate inﬂammation based on production of cytokines and
chemokinesbyepithelialcellsoftheurinarytract.Expression
of adhesive organelles allows UPEC to bind and to invade
the host cells and tissues within the urinary tract. Moreover,
deployment of an array of toxins provides UPEC with the
means to inﬂict an extensive tissue damage, facilitating
bacterial dissemination as well as releasing host nutrients
and disabling the immune eﬀector cells. Recognition of
bacterial products by TLRs activates NF-κB-dependent sig-
naling pathway, leading to translocation of NF-κB into the
nucleus and to expression of proinﬂammatory mediators,
such as IL-6 and IL-8. Additionally, the bladder epithelial
cells activate other NF-κB-independent signaling pathways,
which results in Ca2+, cAMP, PKA, and CREB activation.
UPEC can modulate Ca2+ signaling in the urothelial cells
through several mediators. Altered urothelial Ca2+ signaling
can modulate gene transcription, can stimulate cytokine
expression in response to LPS and TLR4, and can be
initiated by the interaction of UPEC adhesin FimH with
the integral membrane protein UPIIIa to cause urothelial
invasion and apoptosis in the bladder. UPEC possesses also
an ability to interrupt the proinﬂammatory NF-κB signaling.
These ﬁndings suggest more complicated sequence of early
events in the pathogenesis of UTIs that may enhance the
potential for recurrent UTIs. Moreover, recently described
new IRF3 signaling indicates that the genetic variation
in IRF3 inﬂuences individual susceptibility to the kidney
infection and might serve as a new tool for future risk
assessment in this patient group.
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